Previous 10 | Next 10 |
2024-04-22 12:03:00 ET Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom. The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared...
2024-04-21 08:00:00 ET As the market gears up for another eventful earnings week, investors are eagerly anticipating reports from a wide array of companies across various sectors. Big names like Tesla ( NASDAQ: TSLA ), Microsoft ( NASDAQ: MSFT ), Alphabet ( NASDAQ: GOOG ...
2024-04-20 12:03:00 ET Summary abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield of 11.3% and exposure to diverse subsectors of the healthcare industry. The fund outperforms its peers, abrdn World Healthcare Fund (THW) and BlackRock's Health Sciences Trust (BM...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...
2024-04-18 13:59:29 ET Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study i...
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report , which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's report, you will see examples of Gilead's imp...
2024-04-18 13:26:18 ET Summary ALX Oncology's main focus is the CD47 blocker evorpacept, which has shown encouraging results in combination with other therapies for various cancers. The company has a strong financial position with enough runway to fund operations into early 2026. ...
2024-04-18 10:39:58 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Advancing On Several Key Fronts Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Mirum...
2024-04-17 07:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities continue...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...